Form 4 for TVTX Travere Therapeutics, Inc.
Accepted 2026-08-19 16:05:07 ET · period of report 2026-08-17 · accession 0001123343-26-000010 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2026-08-19 16:05 | 2026-08-17+ | TVTX | LYONS GARY A | Dir | M - OptEx | $17.44 | +10.0K | 66.5K | +18% | +$174.4K |
| DMT | 2026-08-19 16:05 | 2026-08-17+ | TVTX | LYONS GARY A | Dir | S - Sale+OE | $63.28 | -10.0K | 61.5K | -14% | -$632.8K |
| DMT | 2026-08-19 16:05 | 2026-08-17+ | TVTX | LYONS GARY A | Dir | M - OptEx | $0.00 | -10.0K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-08-17 | M | A | 5,000 | $17.44 | 66,500 | D | — | — | |
| 2 | Common | Common Stock | 2026-08-17 | S | D | 1,900 | $62.53 | 64,600 | D | — | — | (F1) This sale was made pursuant to a written plan adopted on May 18, 2026 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option granted to the Reporting Person with an expiration date of May 17, 2027. (F2) The weighted average sale price for the transaction reported was $62.5289, and the range of prices were between $62.00 and $62.95. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. |
| 3 | Common | Common Stock | 2026-08-17 | S | D | 2,600 | $63.50 | 62,000 | D | — | — | (F1) This sale was made pursuant to a written plan adopted on May 18, 2026 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option granted to the Reporting Person with an expiration date of May 17, 2027. (F3) The weighted average sale price for the transaction reported was $63.4999, and the range of prices were between $63.01 and $63.94. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. |
| 4 | Common | Common Stock | 2026-08-17 | S | D | 500 | $64.16 | 61,500 | D | — | — | (F1) This sale was made pursuant to a written plan adopted on May 18, 2026 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option granted to the Reporting Person with an expiration date of May 17, 2027. (F4) The weighted average sale price for the transaction reported was $64.1620, and the range of prices were between $64.04 and $64.25. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. |
| 5 | Common | Common Stock | 2026-08-18 | M | A | 5,000 | $17.44 | 66,500 | D | — | — | |
| 6 | Common | Common Stock | 2026-08-18 | S | D | 4,100 | $63.27 | 62,400 | D | — | — | (F1) This sale was made pursuant to a written plan adopted on May 18, 2026 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option granted to the Reporting Person with an expiration date of May 17, 2027. (F5) The weighted average sale price for the transaction reported was $63.2659, and the range of prices were between $62.76 and $63.69. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. |
| 7 | Common | Common Stock | 2026-08-18 | S | D | 900 | $63.86 | 61,500 | D | — | — | (F1) This sale was made pursuant to a written plan adopted on May 18, 2026 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option granted to the Reporting Person with an expiration date of May 17, 2027. (F6) The weighted average sale price for the transaction reported was $63.8557, and the range of prices were between $63.77 and $64.01. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. |
| 8 | Derivative | Stock option (right to buy) | 2026-08-17 | M | D | 5,000 | $0.00 | 5,000 | D | $17.44 · — to 2027-05-17 | 5,000 Common Stock | (F7) The stock option is fully vested and exercisable. |
| 9 | Derivative | Stock option (right to buy) | 2026-08-18 | M | D | 5,000 | $0.00 | 0 | D | $17.44 · — to 2027-05-17 | 5,000 Common Stock | (F7) The stock option is fully vested and exercisable. |